Changes in pediatric health-related quality of life in cystic fibrosis after iv antibiotic treatment for pulmonary exacerbations

Avani C. Modi, Crystal S. Lim, Kimberly A. Driscoll, Carrie Piazza-Waggoner, Alexandra L. Quittner, Jamie Wooldridge

Research output: Contribution to journalArticle

16 Scopus citations


Intravenous (IV) antibiotic therapy for pulmonary exacerbations (PE) has been shown to improve pulmonary functioning for patients with cystic fibrosis (CF); however, little is known about its effects on pediatric health-related quality of life (HRQOL). This prospective study assessed the impact of IV treatment of a PE on generic and CF-specific HRQOL for children and adolescents with CF. Participants included 52 children and adolescents with CF experiencing a PE (M age = 13.6 years; 54% males; M-{{{\text{FEV}}-{1\% } }} predicted = 58.8%). HRQOL, pulmonary functioning, and body mass index were assessed before and after IV antibiotic treatment. Results of this prospective, observational study indicated significant improvements on CFQ-R Respiratory (M change score = 11.7; 95% CI = 6.3-17.1; p < .0001) and Weight (M change score = 15.9; 95% CI = 7.9-23.8; p < .0001) scales. The CF-specific measure was more sensitive to changes in HRQOL than the generic instrument. These data suggest that CF-specific HRQOL improves with treatment for a PE with IV antibiotics. The noted statistically and clinically significant changes in the CFQ-respiratory scale indicate that the measure may be beneficial to pulmonary health care teams.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalJournal of Clinical Psychology in Medical Settings
Issue number1
StatePublished - Mar 1 2010



  • Disease-specific
  • Intravenous antibiotics
  • Minimal clinically important difference
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Clinical Psychology

Cite this